ArticlePloS one2012
Protective effects of fluoxetine on decompression sickness in mice.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04570449 (Fluoxetine to Reduce Hospitalization From COVID-19 Infection), which is not on this map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Systematic review on the effects of medication under hyperbaric conditions: consequences for the diver.Diving and hyperbaric medicine · 2019Pooled it
- Diving and antidepressants.Diving and hyperbaric medicine · 2017Guideline
- Therapeutic Potential of GYY4137 in Reducing Oxidative Stress and Mortality in Experimental Decompression Sickness.Scientific reports · 2026Article
- COInternational journal of environmental research and public health · 2024Article
- Decompression illness: a comprehensive overview.Diving and hyperbaric medicine · 2024Article
- Diving with psychotropic medication: review of the literature and clinical considerations.Diving and hyperbaric medicine · 2023Review
- Therapeutic management of severe spinal cord decompression sickness in a hyperbaric center.Frontiers in medicine · 2023Article
- Demonstration by Infra-Red Imaging of a Temperature Control Defect in a Decompression Sickness Model Testing Minocycline.Frontiers in physiology · 2019Article
- Stimulating fermentation by the prolonged acceleration of gut transit protects against decompression sickness.Scientific reports · 2018Article
- Tirofiban, a Glycoprotein IIb/IIIa Antagonist, Has a Protective Effect on Decompression Sickness in Rats: Is the Crosstalk Between Platelet and Leukocytes Essential?Frontiers in physiology · 2018Article
- Angiotensin Converting Enzyme Inhibitor Has a Protective Effect on Decompression Sickness in Rats.Frontiers in physiology · 2018Article
- Reduction in the Level of Plasma Mitochondrial DNA in Human Diving, Followed by an Increase in the Event of an Accident.Frontiers in physiology · 2018Article
- Preventive effect of rosiglitazone on liver injury in a mouse model of decompression sickness.Diving and hyperbaric medicine · 2017Article
- Thirty-five Day Fluoxetine Treatment Limits Sensory-Motor Deficit and Biochemical Disorders in a Rat Model of Decompression Sickness.Frontiers in physiology · 2017Article
- Fluoxetine Protection in Decompression Sickness in Mice is Enhanced by Blocking TREK-1 Potassium Channel with the "spadin" Antidepressant.Frontiers in physiology · 2016Article
- Methylphenidate and desipramine combined treatment improves PTSD symptomatology in a rat model.Translational psychiatry · 2014Article
- Synergistic effects of celecoxib and bupropion in a model of chronic inflammation-related depression in mice.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Massive bubble formation after diving can lead to decompression sickness (DCS) that can result in central nervous system disorders or even death. Bubbles alter the vascular endothelium and activate blood cells and inflammatory pathways, leading to a systemic pathophysiological process that promotes ischemic damage. Fluoxetine, a well-known antidepressant, is recognized as having anti-inflammatory properties at the systemic level, as well as in the setting of cerebral ischemia. We report a beneficial clinical effect associated with fluoxetine in experimental DCS. 91 mice were subjected to a simulated dive at 90 msw for 45 min before rapid decompression. The experimental group received 50 mg/kg of fluoxetine 18 hours before hyperbaric exposure (n = 46) while controls were not treated (n = 45). Clinical assessment took place over a period of 30 min after surfacing. At the end, blood samples were collected for blood cells counts and cytokine IL-6 detection. There were significantly fewer manifestations of DCS in the fluoxetine group than in the controls (43.5% versus 75.5%, respectively; p = 0.004). Survivors showed a better and significant neurological recovery with fluoxetine. Platelets and red cells were significantly decreased after decompression in controls but not in the treated mice. Fluoxetine reduced circulating IL-6, a relevant marker of systemic inflammation in DCS. We concluded that fluoxetine decreased the incidence of DCS and improved motor recovery, by limiting inflammation processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.